评价白蛋白相关药物动物模型的研究进展  

Advances in animal models for albumin⁃related drug studies

作　　者：资崯 宁丽 周小青 唐成程 ZI Yin;NING Li;ZHOU Xiaoqing;TANG Chengcheng(Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine,South China Institute of Large Animal Models for Biomedicine,School of Biotechnology and Health Science,Wuyi University,Jiangmen 529000,China)

机构地区：[1]广东省医学大动物模型重点实验室,华南生物医药大动物模型研究院,生物科技与大健康学院,五邑大学,广东江门529000

出　　处：《中国实验动物学报》2023年第10期1374-1380,共7页Acta Laboratorium Animalis Scientia Sinica

基　　金：广东省自然科学基金(2019A1515110283);江门市科技计划项目(2021030101230004833,2021030101220004887)。

摘　　要：许多肽或蛋白质药物治疗的一个主要挑战是血浆半衰期短。通过将该类药物与白蛋白结合获得的药物称为白蛋白相关药物,有效延长血浆半衰期。动物模型作为研究药物药代动力学的重要工具是药物研究中不可或缺的一部分。本综述概括了两大类动物模型:啮齿类(野生型小鼠、大鼠模型,基因修饰小鼠模型)与非啮齿(猴)在白蛋白相关药物药代动力学研究中的应用与发展,为其进一步研究发展提供参考。The main challenge of therapeutic peptides and proteins is their short plasma half-life due to rapid protease degradation.Drugs combining such peptides and proteins with albumin are defined as albumin-related drugs.Such a combination effectively prolongs their plasma half-life.Animal models are an important and indispensable tool to study drug pharmacokinetics.This review summarizes the two main animal models,rodents(wildtype mice,gene-modified mouse models,and rat models)and non-human primates(monkeys),and their development and application in albumin-related drugs.This review provides a reference for further studies on albumin-related drugs.

关 键 词：白蛋白相关药物 血浆半衰期 动物模型 

分 类 号：Q95-33[生物学—动物学]